Clinical Trial: A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.

U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07429721) titled 'A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.' on Feb. 11.

Brief Summary: This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019A in patients with relapsed/refractory multiple myeloma.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma (MM)

Intervention: DRUG: QI-019A Injection

QI-019A Injection is an in vivo administered CAR-T gene therapy product that uses a lentiviral vector as the delivery system. Its mec...